Geode Capital Management’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $123M | Buy |
1,258,502
+342,291
| +37% | +$29.9M | 0.01% | 1064 |
|
|
2026
Q1 | $76.9M | Buy |
916,211
+239,553
| +35% | +$13.9M | ﹤0.01% | 1246 |
|
|
2025
Q4 | $27.9M | Buy |
676,658
+140,243
| +26% | +$5.44M | ﹤0.01% | 1834 |
|
|
2025
Q3 | $21.1M | Buy |
536,415
+51,515
| +11% | +$1.32M | ﹤0.01% | 1974 |
|
|
2025
Q2 | $9.04M | Sell |
484,900
-32,118
| -6% | -$603K | ﹤0.01% | 2428 |
|
|
2025
Q1 | $9.38M | Buy |
517,018
+30,755
| +6% | +$678K | ﹤0.01% | 2331 |
|
|
2024
Q4 | $10.6M | Buy |
486,263
+1,142
| +0.2% | +$29.4K | ﹤0.01% | 2344 |
|
|
2024
Q3 | $13.3M | Sell |
485,121
-13,799
| -3% | -$384K | ﹤0.01% | 2205 |
|
|
2024
Q2 | $12.9M | Buy |
498,920
+424,520
| +571% | +$10.2M | ﹤0.01% | 2170 |
|
|
2024
Q1 | $2.23M | Buy |
74,400
+29,221
| +65% | +$635K | ﹤0.01% | 3073 |
|
|
2023
Q4 | $470K | Buy |
45,179
+18,838
| +72% | +$208K | ﹤0.01% | 3640 |
|
|
2023
Q3 | $360K | Buy |
26,341
+3,985
| +18% | +$50.2K | ﹤0.01% | 3730 |
|
|
2023
Q2 | $271K | Hold |
22,356
| – | – | ﹤0.01% | 3904 |
|
|
2023
Q1 | $284K | Hold |
22,356
| – | – | ﹤0.01% | 3883 |
|
|
2022
Q4 | $141K | Buy |
22,356
+454
| +2% | +$8.04K | ﹤0.01% | 4257 |
|
|
2022
Q3 | $494K | Buy |
21,902
+410
| +2% | +$11.2K | ﹤0.01% | 3737 |
|
|
2022
Q2 | $412K | Sell |
21,492
-15,589
| -42% | -$385K | ﹤0.01% | 3866 |
|
|
2022
Q1 | $1.72M | Buy |
37,081
+2,585
| +7% | +$141K | ﹤0.01% | 3334 |
|
|
2021
Q4 | $2.44M | Buy |
34,496
+1,479
| +4% | +$149K | ﹤0.01% | 3275 |
|
|
2021
Q3 | $3.85M | Buy |
33,017
+1,568
| +5% | +$183K | ﹤0.01% | 3065 |
|
|
2021
Q2 | $4.92M | Buy |
31,449
+6,212
| +25% | +$1.14M | ﹤0.01% | 2922 |
|
|
2021
Q1 | $4.78M | Buy |
25,237
+7,244
| +40% | +$1.22M | ﹤0.01% | 2811 |
|
|
2020
Q4 | $2.26M | Sell |
17,993
-34
| -0.2% | -$3.85K | ﹤0.01% | 3018 |
|
|
2020
Q3 | $1.96M | Buy |
18,027
+532
| +3% | +$63K | ﹤0.01% | 2880 |
|
|
2020
Q2 | $2.1M | Buy |
17,495
+555
| +3% | +$78.2K | ﹤0.01% | 2810 |
|
|
2020
Q1 | $1.7M | Buy |
16,940
+775
| +5% | +$144K | ﹤0.01% | 2757 |
|
|
2019
Q4 | $3.92M | Buy |
16,165
+946
| +6% | +$177K | ﹤0.01% | 2603 |
|
|
2019
Q3 | $2.5M | Buy |
15,219
+201
| +1% | +$38.2K | ﹤0.01% | 2803 |
|
|
2019
Q2 | $3.54M | Buy |
15,018
+7,459
| +99% | +$1.84M | ﹤0.01% | 2610 |
|
|
2019
Q1 | $1.99M | Buy |
7,559
+6,200
| +456% | +$1.07M | ﹤0.01% | 2858 |
|
|
2018
Q4 | $123K | Buy |
1,359
+408
| +43% | +$55.6K | ﹤0.01% | 3825 |
|
|
2018
Q3 | $182K | Buy |
+951
| New | +$200K | ﹤0.01% | 3787 |
|
Other funds holding DNTH
FFM
APM
OCA
Geode Capital Management's DNTH Position: Q2 2026 in Review
Geode Capital Management increased its Dianthus Therapeutics (DNTH) stake by 37% in Q2 2026, buying an estimated $29.9M and bringing the position to 1,258,502 shares worth $123M. The position accounts for 0.01% of the portfolio, ranked #1064.
Geode Capital Management first reported a position in DNTH in Q3 2018 and has held it in 32 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Geode Capital Management held 1,258,502 shares of Dianthus Therapeutics worth $123M as of Q2 2026.
- Geode Capital Management bought 342,291 Dianthus Therapeutics shares in Q2 2026, an estimated $29.9M.
- Dianthus Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #1064 holding.
- Geode Capital Management first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 32 quarters since.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.